Top in endocrinology: Contaminated metformin products, high-fat dairy intake
Click Here to Manage Email Alerts
The FDA has requested a voluntary recall of several lots of extended-release metformin. It was the top story in endocrinology last week.
Another top story was about an association between higher whole-fat dairy intake and a lower prevalence of metabolic syndrome, hypertension and diabetes.
Source: Adobe Stock.
Read these and more top stories in endocrinology below:
FDA requests voluntary recall of contaminated metformin products
The FDA has asked five drug manufacturers to voluntarily recall several lots of extended-release metformin after agency lab testing revealed unacceptable levels of the nitrosamine impurity N-Nitrosodimethylamine. Read more.
Consuming high-fat dairy tied to less metabolic syndrome, diabetes, hypertension
Higher intake of whole-fat — but not low-fat — dairy is associated with a lower prevalence of metabolic syndrome, as well as lower incidence of hypertension and diabetes, researchers reported. Read more.
Long-term data lacking for hydroxychloroquine use in type 2 diabetes, COVID-19
Evidence suggests hydroxychloroquine may play a role in glucose homeostasis among select individuals with type 2 diabetes; however, data on long-term safety and efficacy are lacking, particularly in the setting of COVID-19. Read more.
In ESRD, bariatric surgery lowers risk for death, ups odds for transplant
Adults with obesity receiving dialysis treatment who underwent bariatric surgery were 30% less likely to die of any cause and 82% more likely to undergo kidney transplantation at 5 years compared with similar adults receiving usual care. Read more.
Realize the potential of adjunctive therapy in the treatment of type 1 diabetes
One approach to improve care and clinical outcomes for people with type 1 diabetes involves the use of adjunctive therapies along with insulin to improve glucose control or enable reductions in insulin doses. Read more.